The odds of having gastro-oesophageal reflux disease (GORD/GERD) is nearly two times higher in patients with idiopathic pulmonary fibrosis (IPF) compared with adults without the lung condition, a study claims.
IPF is a lung condition that scars the lungs (fibrosis) and reduces breathing efficiency. Idiopathic means the cause is not known but research suggests the body creates fibrosis in response to injury to the lung.
According to the British Lung Foundation, about 6,000 people are diagnosed with IPF every year in the UK. Nearly 80 per cent are men, and on average, about three quarters are over 73.
In a new US study, researchers found that patients with IPF were more likely to have a diagnosis of GERD/GORD (43.4 per cent vs. 28.5 per cent) and were more likely to be current smokers (15.9 per cent vs. 3.6 per cent) compared with controls.
The odds of GERD diagnosis were 1.78 times higher among patients with IPF compared with patients in a population control group.
The Idiopathic Pulmonary Fibrosis and Gastroesophageal Reflux Disease: A Population-based, Case-Control study was recently published in international journal Respiratory Medicine.
Researchers of the study concluded: “GERD may be an important contributor to the development of lung fibrosis. Thus, it should be investigated and addressed adequately when detected in patients with IPF and patients with non-IPF interstitial lung disease.”
Previously, a study has suggested that detection of pepsin using Peptest could provide objective evidence of a contribution of airways reflux in the pathology of a range of pulmonary diseases, such as idiopathic pulmonary fibrosis, chronic cough, bronchial asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis.
An early and objective diagnosis of reflux, such as Peptest provides, opens the door to lifestyle changes, and future treatment.
Peptest can also be used after reflux treatments to assess the success or failure of any treatment.
Find out more about Peptest and order your Peptest home testing kit now.